Risk of renal cell carcinoma in relation to blood telomere length in a population-based case–control study by Hofmann, J N et al.
 
Risk of renal cell carcinoma in relation to blood telomere length in
a population-based case–control study
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Hofmann, J N, A Baccarelli, K Schwartz, F G Davis, J J
Ruterbusch, M Hoxha, B J McCarthy, et al. 2011. Risk of renal
cell carcinoma in relation to blood telomere length in a
population-based case–control study. British Journal of Cancer
105(11): 1772-1775.
Published Version doi:10.1038/bjc.2011.444
Accessed February 19, 2015 11:52:41 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10578872
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAShort Communication
Risk of renal cell carcinoma in relation to blood telomere length in
a population-based case–control study













1 and MP Purdue
1
1Division of Cancer Epidemiology and Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute, 6120 Executive
Boulevard, EPS 8109, Bethesda, MD 20892-7240, USA;
2Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA;
3Department of Family Medicine and Public Health Sciences, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA;
4Division of
Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, USA;
5Department of Occupational and Environmental
Health, University of Milan and Ca’ Granda Ospedale Maggiore Policlinico Hospital IRCCS Foundation, Milan, Italy
BACKGROUND: There are few known risk factors for renal cell carcinoma (RCC). Two small hospital-based case–control studies
suggested an association between short blood telomere length (TL) and increased RCC risk.
METHODS: We conducted a large population-based case–control study in two metropolitan regions of the United States comparing
relative TL in DNA derived from peripheral blood samples from 891 RCC cases and 894 controls. Odds ratios and 95% confidence
intervals were estimated using unconditional logistic regression in both unadjusted and adjusted models.
RESULTS: Median TL was 0.85 for both cases and controls (P¼0.40), and no differences in RCC risk by quartiles of TL were observed.
Results of analyses stratified by age, sex, race, tumour stage, and time from RCC diagnosis to blood collection were similarly null. In
multivariate analyses among controls, increasing age and history of hypertension were associated with shorter TL (Po0.001 and
P¼0.07, respectively), and African Americans had longer TL than Caucasians (Po0.001).
CONCLUSION: These data do not support the hypothesis that blood TL is associated with RCC. This population-based case–control
study is, to our knowledge, the largest investigation to date of TL and RCC.
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Telomeres are nucleotide repeats and a protein complex at
chromosome ends that are essential for chromosomal stability.
Telomere attrition occurs with each cell division due to inefficient
replication at the ends of linear DNA. Critically short telomeres
trigger cellular senescence and death, but cancer cells divide
despite the resultant genomic instability. Telomere length (TL) is a
suspected marker of cancer risk (De Lange, 2005). Two small
hospital-based case–control studies (32 and 65 cases, respectively)
reported an increased risk of renal cell carcinoma (RCC) in
relation to shorter TL (Wu et al, 2003; Shao et al, 2007). To follow
up on these findings, we evaluated RCC risk in relation to TL in a
large case–control study.
MATERIALS AND METHODS
Study population, data and sample collection, and
sample processing
Subject recruitment and data and specimen collection methods
have been described (Colt et al, 2011). Briefly, this population-
based case–control study of Caucasians and African Americans
was conducted in Detroit, MI, USA (Wayne, Oakland, and Macomb
Counties) from 2002–2007, and in Chicago, IL, USA (Cook
County) in 2003; according to US census estimates from 2000, the
populations of these two metropolitan areas had generally similar
racial distributions (56.3% Caucasian and 26.1% African American
in Cook County; 68.9% Caucasian and 25.0% African American in
Wayne, Oakland, and Macomb Counties, combined). To maximise
enrolment of African Americans, we over-sampled African
American cases relative to Caucasian cases, and we frequency
matched controls to cases at a 2:1 ratio for African Americans and
a 1:1 ratio for Caucasians to increase statistical power for analyses
stratified by race. Subjects with stored blood samples (whole blood
or buffy coat) were included in this analysis. Eight cases with
benign tumours, non-RCC histology, or cancer in a transplanted
kidney were excluded. Telomere length could not be measured for
one control subject, who was also excluded, leaving 891 cases (658
Caucasians and 233 African Americans) and 894 controls (550
Caucasians and 344 African Americans). Blood samples were
collected from cases and controls at the time of the personal
interview. Among cases, the median time from RCC diagnosis to
blood sample collection was B4 months. Samples of DNA were
extracted via Qiagen kits; DNA was derived from whole blood
samples for most study subjects (cases: 627 whole blood, 264 buffy
coat; controls: 768 whole blood, 126 buffy coat). The distribution
of the source material for DNA extraction was similar for each
study centre. Study procedures were approved by Institutional
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yReview Boards at collaborating institutions, and written informed
consent was obtained from all subjects.
TL measurements
A quantitative PCR assay was used to measure TL; assay methods
have been described (Cawthon, 2002). Briefly, telomere repeat (T)
and single gene (S) copy numbers were measured in individual
samples and adjusted in comparison to standard reference DNA; the
standardised T/S ratio characterises relative TL. In TL measure-
ments for blinded duplicate QC samples from 59 subjects, the
coefficient of variation (CV) was 9.9% and the intraclass correlation
coefficient was 0.85 (95% confidence interval (CI): 0.76, 0.91).
Statistical analysis
Telomere length data were natural log-transformed to achieve a
normal distribution. We compared TL between cases and controls,
and evaluated differences in TL by demographic and personal
characteristics among controls in bivariate and multivariate
analyses. Odds ratios (ORs) and 95% CIs were calculated using
unconditional logistic regression. Quartiles of TL were determined
based on the distribution among controls. Adjusted analyses
included terms for age (10-year categories), sex, race, smoking,
body mass index (BMI), history of hypertension, education, study
centre, and material type (whole blood or buffy coat). Analyses
stratified by these covariates, tumour stage/grade, RCC treatment
modality, and time from RCC diagnosis to blood collection were
also performed.
RESULTS
Cases and controls had similar age and sex distributions. Cases
were more likely to be obese (BMIX30), to smoke, and to have a
history of hypertension, as reported previously (Karami et al,
2010). The vast majority of cases with treatment information
available had surgery alone without adjuvant therapy (N¼803;
92%), and most cases with information on stage at diagnosis had
localised disease (N¼611; 81%).
Median relative TL (5th–95th percentile distributions) was 0.85
(0.58–1.25) and 0.85 (0.58–1.23) for cases and controls, respec-
tively (P¼0.40, Wilcoxon rank sum test). A box plot showing the
distribution of TL measurements among cases and controls is
available online (Supplementary Figure 1). No differences in TL
between cases and controls were observed after stratifying by
material type. The expected age-related decline in TL was observed
in both cases and controls. In multivariate analyses among
controls, TL was significantly longer among African Americans
than among Caucasians (Po0.001), and we observed a borderline
significant association between hypertension and shorter TL
(P¼0.07; Table 1).
No overall associations between TL and RCC were observed
(Table 2). Analyses stratified by sex, race, age, or other variables
did not reveal any consistent subgroup-specific associations
between TL and RCC. No differences in the relationship between
TL and RCC by tumour stage (localised vs other) were observed,
nor when we restricted our analysis to cases treated by surgery
alone. We did not observe any differences in TL by days from RCC
diagnosis to blood collection (adjusted b¼ 2.95 10
 5; 95% CI:
 9.01 10
 5, 3.11 10
 5), and risk estimates did not differ after
stratifying by time since diagnosis (data not shown).
DISCUSSION
The results of this case–control study do not support the
hypothesis that blood TL is associated with RCC. Our study did
not replicate findings from two hospital-based case–control
studies with 32 and 65 RCC cases, respectively, that reported an
inverse association between TL and RCC (Wu et al, 2003; Shao
et al, 2007). Both prior studies measured TL using a Q-FISH assay;
it has been demonstrated that Q-FISH measurements are highly
correlated with measurements by the QPCR method used in this
study (Cawthon, 2002). Because measurements in our study were
highly reproducible in blind replicates (CV¼9.9%), it is unlikely
that measurement error could explain the difference in findings
between our study and previous studies.
This population-based case–control study is, to our knowledge,
the largest investigation of TL and RCC to date. We had 89% power
to detect a trend in ORs with decreasing quartiles of TL assuming an
OR of 1.5 comparing the lowest and highest quartiles. Our findings
of shorter TL with increasing age and history of hypertension are
consistent with previous reports (Demissie et al, 2006; Mirabello
et al, 2009), which supports the validity of these findings.
Differences in TL by race are inconsistent in previous studies
(Hunt et al, 2008; Roux et al, 2009) and additional research is
needed to confirm these findings. Numerous studies have
investigated TL in relation to smoking and BMI (Wu et al, 2003;
Table 1 Determinants of blood telomere length among controls
a











o45 128 1.00 (0.97, 1.04) Ref
45–54 198 0.88 (0.85, 0.91) –10% (–15%, –6%)*
55–64 255 0.82 (0.80, 0.85) –15% (–19%, –11%)*
65–74 237 0.79 (0.77, 0.82) –18% (–22%, –14%)*
75+ 76 0.78 (0.74, 0.83) –18% (–23%, –13%)*
Ptrendo0.001 Ptrendo0.001
Sex
Female 381 0.86 (0.84, 0.89) Ref
Male 513 0.83 (0.82, 0.85) –2% (–5%, 1%)
Race
Caucasian 550 0.82 (0.81, 0.84) Ref
African American 344 0.89 (0.86, 0.91) 9% (5%, 12%)*
Hypertension
Never 525 0.87 (0.85, 0.89) Ref
Ever 364 0.81 (0.79, 0.83) –3% (–6%, 0%)**
Smoking status
Never 346 0.86 (0.84, 0.89) Ref
Occasional 41 0.87 (0.80, 0.95) –1% (–7%, 6%)
Former 331 0.83 (0.81, 0.85) 0% (–3%, 3%)
Current 175 0.85 (0.82, 0.88) –2% (–6%, 2%)
BMI
o25 256 0.85 (0.83, 0.88) Ref
25–29.9 366 0.84 (0.82, 0.86) 2% (–2%, 5%)
30–34.9 155 0.86 (0.82, 0.89) 3% (–2%, 7%)
35+ 114 0.84 (0.80, 0.88) 0% (–5%, 5%)
Source of DNA specimen
Whole blood 768 0.83 (0.82, 0.85) Ref
Buffy coat 126 0.95 (0.91, 0.99) 10% (5%, 15%)*
Abbreviations: CI¼confidence interval; BMI¼body mass index.
aTelomere length
measurements were expressed as the standardised T/S ratio, and data were natural
log-transformed for all analyses.
bEach variable was evaluated after adjusting for all
other covariates reported above as well as study centre and level of education. Nine
controls with missing data for any variable were excluded from this analysis.
cThe
percent difference in the geometric mean relative to the reference category was
estimated using the formula (exp(b)–1). *Po0.001. **P¼0.07.
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yTable 2 Risk of renal cell carcinoma in relation to blood telomere length
a
Telomere length quartile
b Ncases Ncontrols Unadjusted OR (95% CI) Adjusted OR (95% CI)
c
Overall
4th Quartile 259 222 Ref Ref
3rd Quartile 177 224 0.68 (0.52, 0.88) 0.69 (0.51, 0.93)
2nd Quartile 242 224 0.93 (0.72, 1.20) 0.90 (0.67, 1.20)





4th Quartile 116 102 Ref Ref
3rd Quartile 80 108 0.65 (0.44, 0.96) 0.68 (0.43, 1.09)
2nd Quartile 104 82 1.12 (0.75, 1.65) 1.11 (0.69, 1.79)
1st Quartile 69 89 0.68 (0.45, 1.03) 0.60 (0.36, 0.99)
Ptrend¼0.28 Ptrend¼0.17
Men
4th Quartile 143 120 Ref Ref
3rd Quartile 97 116 0.70 (0.49, 1.01) 0.73 (0.49, 1.08)
2nd Quartile 138 142 0.82 (0.58, 1.14) 0.82 (0.56, 1.19)




4th Quartile 80 107 Ref Ref
3rd Quartile 44 86 0.68 (0.43, 1.09) 0.73 (0.43, 1.26)
2nd Quartile 57 87 0.88 (0.56, 1.36) 0.73 (0.43, 1.23)
1st Quartile 52 64 1.09 (0.68, 1.73) 0.84 (0.48, 1.46)
Ptrend¼0.85 Ptrend¼0.42
Caucasian
4th Quartile 179 115 Ref Ref
3rd Quartile 133 138 0.62 (0.44, 0.86) 0.69 (0.48, 0.99)
2nd Quartile 185 137 0.87 (0.63, 1.20) 0.97 (0.68, 1.39)
1st Quartile 161 160 0.65 (0.47, 0.89) 0.76 (0.53, 1.10)
Ptrend¼0.04 Ptrend¼0.32
Age
Under 60 years of age
4th Quartile 177 160 Ref Ref
3rd Quartile 99 123 0.73 (0.52, 1.02) 0.81 (0.55, 1.20)
2nd Quartile 103 105 0.89 (0.63, 1.25) 1.00 (0.67, 1.49)
1st Quartile 80 67 1.08 (0.73, 1.59) 1.29 (0.83, 2.02)
Ptrend40.99 Ptrend¼0.36
60+ years of age
4th Quartile 82 62 Ref Ref
3rd Quartile 78 101 0.58 (0.38, 0.91) 0.60 (0.38, 0.96)
2nd Quartile 139 119 0.88 (0.59, 1.33) 0.85 (0.55, 1.32)
1st Quartile 133 157 0.64 (0.43, 0.96) 0.62 (0.40, 0.95)
Ptrend¼0.13 Ptrend¼0.09
Source of DNA specimen
Whole blood
d
4th Quartile 145 192 Ref Ref
3rd Quartile 139 192 0.96 (0.71, 1.30) 0.78 (0.55, 1.10)
2nd Quartile 180 192 1.24 (0.92, 1.67) 0.88 (0.63, 1.23)




4th Quartile 72 32 Ref Ref
3rd Quartile 55 31 0.79 (0.43, 1.45) 0.68 (0.35, 1.32)
2nd Quartile 68 32 0.94 (0.52, 1.71) 0.80 (0.41, 1.57)
1st Quartile 69 31 0.99 (0.55, 1.79) 1.11 (0.56, 2.21)
Ptrend¼0.90 Ptrend¼0.70
Abbreviations: OR¼odds ratio; CI¼confidence interval; BMI¼body mass index.
aTelomere length measurements were expressed as the standardised T/S ratio.
bQuartiles
were determined based on the distribution of telomere length measurements among controls. Cut points were defined as follows: Q1, p0.7288; Q2, 0.7289–0.8535; Q3,
0.8536–0.9795; and Q4, X0.9796.
cAdjusted for the following covariates: sex, age, race, smoking status, BMI, history of hypertension, level of education, study centre (Detroit or
Chicago), and material type (whole blood or buffy coat). In all, 30 subjects with missing data for smoking status, BMI, or history of hypertension were excluded from this analysis.
dQuartiles based on the distribution of telomere length measurements among controls with whole blood samples. Cut points were defined as follows: Q1, p0.7197; Q2,
0.7198–0.8341; Q3, 0.8342–0.9633; and Q4, X0.9634.
eQuartiles based on the distribution of telomere length measurements among controls with buffy coat samples. Cut
points were defined as follows: Q1, p0.8323; Q2, 0.8324–0.9651; Q3, 0.9652–1.1048; and Q4, X1.1049.
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yValdes et al, 2005; Nordfjall et al, 2008; Kim et al, 2009; Mirabello
et al, 2009; Fitzpatrick et al, 2011; Lee et al, 2011; Shen et al, 2011).
Overall, the totality of the evidence linking these exposures to TL is
inconsistent, with only some studies reporting inverse associations
with smoking (Valdes et al, 2005; Mirabello et al, 2009; Fitzpatrick
et al, 2011; Shen et al, 2011) and BMI (Valdes et al, 2005; Nordfjall
et al, 2008; Kim et al, 2009; Lee et al,2 0 1 1 ) .
Measurement of TL in samples collected retrospectively is an
inherent limitation of case–control studies. Previous studies of
various cancers have reported strong associations between short
TL and cancer risk in retrospective studies but not in studies with
prospective sample collection (Pooley et al, 2010; Wentzensen
et al, 2011). However, in our study, we did not observe any
differences in the relation between TL and RCC after stratifying by
tumour stage, tumour grade, and time from RCC diagnosis to
blood collection, nor when we restricted to cases treated by surgery
only. Furthermore, Svenson et al (2009) found that among cases
with non-metastatic disease (consistent with most of the cases
included in our study) TL was not related to survival until 410
months after RCC diagnosis. Since the vast majority of samples in
our study were collected from RCC cases within 10 months of
diagnosis, we would not expect our findings to be biased as a result
of differential survival. Moreover, since long TL was associated
with poor survival, any bias due to a survival effect would be
expected to exaggerate (rather than to obscure) an association
between short TL and RCC risk. Given this evidence from our
study and the analysis by Svenson et al (2009), it is unlikely that
disease- or treatment-related changes in TL would have affected
our findings. In conclusion, we found no evidence of an
association between blood TL and RCC risk in this population-
based case–control study, to our knowledge the largest such
investigation to date.
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